Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents [3]

Leukemia

Volumn 17, Issue 8, 2003, Pages 1669-1670

  Visani, G ^a   Mele, A ^a   Malagola, M ^b   Isidori, A ^b   Finelli, C ^b   Piccaluga, P P ^b  

^a SAN SALVATORE HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; HYDROXYUREA; RECOMBINANT ERYTHROPOIETIN; STEROID; THALIDOMIDE; VINDESINE;

ADULT; ANEMIA; BLOOD TRANSFUSION; CASE REPORT; CONSTIPATION; DISEASE CONTROL; DRUG POTENTIATION; FLUID RETENTION; HUMAN; LETTER; MALE; MONOTHERAPY; MYELOFIBROSIS; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0043028640     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403017     Document Type: Letter

References (8)

1. Reilly JT. Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Rev 1997; 11: 2133.
2. Barosi G, Grossi A, Comotti B, Musto P, Gamba G, Marchetti M. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2001; 114: 78-83.
3. Canepa L, Ballerini F, Varaldo R, Quintino S, Reni L, Clavio M et al. Thalidomide in angiogenic and secondary myelofibrosis. Br J Haematol 2001; 115: 313-315.
4. Pozzato G, Zorat F, Nascimben F, Comar C, Kikic F, Festini G. Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia. Haematologica 2001; 86: 772-773.
5. Elliott MA, Mesa RA, Li C-Y, Hook CC, Ansell MA, Levitt RM et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 117: 288-296.
6. Piccaluga PP, Visani G, Pileri SA, Ascani S, Grafone T, Isidori A et al. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia 2002; 16: 1609-1614.
7. Rodriguez JN, Martino ML, Dieguez JC, Prados D. RHuEPO for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach. Haematologica 1998; 83: 616-621.
8. Visani G, Finelli C, Castelli U, Petti MC, Ricci P, Vianelli N et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematology 1990; 75: 4-9.